Genpact LTD (G) — SEC Filings

Overview

Genpact LTD (G) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Nov 18, 2025: On November 18, 2025, Genpact Limited entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obligation under an off-balance sheet arrangement for the registrant. The report includes financial statements and exhibits related to th

Sentiment Summary

Across 35 filings, the sentiment breakdown is: 3 bullish, 31 neutral, 1 mixed. The dominant filing sentiment for Genpact LTD is neutral.

Filing Type Overview

Genpact LTD (G) has filed 16 8-K, 6 10-Q, 2 DEFA14A, 2 DEF 14A, 2 10-K, 7 SC 13G/A with the SEC between Jan 2024 to Nov 2025.

Filings by Year

2025 · 2024

Recent Filings (35)

• Genpact Ltd. Files 8-K for Material Agreement — 8-K · Nov 18, 2025 Risk: medium
  On November 18, 2025, Genpact Limited entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or
• Genpact's Revenue, Net Income Climb; Acquisitions Drive Investment Spend — 10-Q · Nov 7, 2025 Risk: medium
  Genpact LTD reported a robust financial performance for the nine months ended September 30, 2025, with net revenues increasing by 6.89% to $3,760,601 thousand f
• 8-K Filing — 8-K · Nov 6, 2025
• Genpact Limited Reports Director and Officer Changes — 8-K · Sep 30, 2025 Risk: medium
  Genpact Limited filed an 8-K on September 30, 2025, reporting changes effective September 29, 2025. The filing pertains to the departure of directors, election
• Genpact Limited Reports Director Changes and Officer Compensation Updates — 8-K · Sep 12, 2025 Risk: low
  Genpact Limited announced on September 11, 2025, changes in its board and executive compensation. Specifically, the company reported the departure of a director
• Genpact Q2 Earnings Soar 15.6% on Strong Digital Demand — 10-Q · Aug 11, 2025 Risk: medium
  Genpact LTD reported a robust financial performance for the second quarter ended June 30, 2025, and the six months ended June 30, 2025. The company's revenue fo
• Genpact Limited Files 8-K on Financials — 8-K · Aug 7, 2025 Risk: low
  Genpact Limited filed an 8-K on August 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exh
• Genpact Limited Reports Director Changes and Compensation Updates — 8-K · Aug 5, 2025 Risk: low
  Genpact Limited announced on July 31, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the de
• Genpact Limited Files 8-K on Director and Officer Changes — 8-K · Jul 1, 2025 Risk: medium
  On July 1, 2025, Genpact Limited filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates a shift in cor
• Genpact Limited Files 8-K on Shareholder Vote Matters — 8-K · May 28, 2025 Risk: low
  Genpact Limited filed an 8-K on May 28, 2025, reporting on matters submitted to a vote of security holders as of May 22, 2025. The filing indicates a submission
• Genpact Ltd. Files Q1 2025 10-Q Report — 10-Q · May 12, 2025 Risk: low
  Genpact Ltd. filed its 10-Q for the period ending March 31, 2025. The filing covers the first quarter of 2025 and provides financial updates. Key financial data
• Genpact Limited Files 8-K on Financials — 8-K · May 7, 2025 Risk: low
  Genpact Limited filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibi
• Genpact Ltd. Files Proxy Statement Supplement — DEFA14A · May 6, 2025 Risk: low
  Genpact Limited filed a Definitive Additional Materials (DEFA14A) on May 6, 2025, as a supplement to its proxy statement for the Annual General Meeting of Share
• Genpact Files Definitive Proxy Statement for 2025 Annual Meeting — DEF 14A · Apr 9, 2025 Risk: low
  Genpact Limited filed a definitive proxy statement (DEF 14A) on April 9, 2025, for its annual meeting on May 22, 2025. The filing concerns the solicitation of p
• Genpact Ltd. Files 2024 Annual Report — 10-K · Mar 3, 2025 Risk: medium
  Genpact Ltd. filed its 10-K for the fiscal year ending December 31, 2024, on March 3, 2025. The filing provides a comprehensive overview of the company's financ
• Genpact Limited Files 8-K on Financials — 8-K · Feb 6, 2025 Risk: low
  Genpact Limited filed an 8-K on February 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and e
• Genpact Ltd. Files Q3 2024 10-Q Report — 10-Q · Nov 12, 2024 Risk: low
  Genpact Ltd. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter of
• SC 13G/A Filing — SC 13G/A · Nov 12, 2024
• Genpact Limited Files 8-K on Financials — 8-K · Nov 7, 2024 Risk: low
  Genpact Limited filed an 8-K on November 7, 2024, reporting on its results of operations and financial condition, and including financial statements and exhibit
• Genpact Ltd. Files Q2 2024 10-Q Report — 10-Q · Aug 9, 2024 Risk: low
  Genpact Ltd. filed its 10-Q for the period ending June 30, 2024. The filing covers the second quarter of 2024, detailing financial performance and operational u
• Genpact Limited Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
  On August 8, 2024, Genpact Limited filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as fi
• SC 13G/A Filing — SC 13G/A · Jun 6, 2024
• Genpact LTD Files 8-K: Material Agreement & Financial Obligation — 8-K · Jun 4, 2024 Risk: medium
  On May 30, 2024, Genpact Limited entered into a material definitive agreement, likely related to financing or a significant operational transaction. This filing
• Genpact Ltd. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: low
  Genpact LTD (G) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. Genpact Ltd. filed a 10-Q report for the period ending March 31, 2024. The filing
• Genpact Limited Files 8-K on Financials — 8-K · May 9, 2024 Risk: low
  Genpact Limited filed an 8-K on May 9, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibi
• Genpact Limited Files 8-K on Shareholder Votes — 8-K · May 8, 2024 Risk: low
  Genpact Limited filed an 8-K on May 8, 2024, reporting on matters submitted to a vote of security holders as of May 2, 2024. The filing details the company's co
• Genpact Ltd Files Definitive Proxy Statement — DEFA14A · Apr 10, 2024 Risk: low
  Genpact Limited filed a Definitive Proxy Statement (DEFA14A) on April 10, 2024. This filing is a standard proxy statement used to solicit votes from shareholder
• Genpact Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Mar 20, 2024 Risk: low
  Genpact LTD (G) filed a Proxy Statement (DEF 14A) with the SEC on March 20, 2024. Total revenue reached $4.48 billion, a 2% increase year-over-year (3% on a con
• Genpact Ltd. Files 2023 Annual Report on Form 10-K — 10-K · Feb 29, 2024 Risk: medium
  Genpact LTD (G) filed a Annual Report (10-K) with the SEC on February 29, 2024. Genpact Ltd. filed its 2023 Form 10-K on February 29, 2024, reporting on the fis
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• FMR LLC & Abigail Johnson Maintain 11.747% Stake in Genpact LTD — SC 13G/A · Feb 9, 2024 Risk: low
  FMR LLC, a major investment firm, and its principal owner, Abigail P. Johnson, have updated their ownership stake in Genpact LTD. As of February 9, 2024, they c
• Genpact Files 8-K for Financial Results Release on Feb 8, 2024 — 8-K · Feb 8, 2024 Risk: low
  Genpact LTD filed an 8-K on February 8, 2024, under Items 2.02 and 9.01, indicating the release of their financial results and related exhibits. This filing is
• Wellington Mgmt Amends Genpact Stake, Signals Portfolio Shift — SC 13G/A · Feb 8, 2024 Risk: low
  Wellington Management Group LLP filed an amended SC 13G/A on February 8, 2024, indicating a change in their ownership of Genpact Limited's common stock as of De
• BlackRock Boosts Genpact Stake to 14.1% as of Jan 31, 2024 — SC 13G/A · Feb 7, 2024
  BlackRock Inc. filed an amended SC 13G/A on February 7, 2024, disclosing its ownership in Genpact LTD. As of January 31, 2024, BlackRock Inc. holds 26,082,789 s
• BlackRock Amends Genpact Stake, Maintains Significant Holding — SC 13G/A · Jan 24, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 24, 2024, disclosing its ownership in Genpact LTD's Common Stock as of December 31, 2023. This filing indica

Risk Profile

Risk Assessment: Of G's 29 recent filings, 0 were flagged as high-risk, 8 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Genpact LTD's most recent 10-Q filing (Nov 7, 2025):

• Revenue: $3.76B
• Net Income: $409.4M
• EPS: $2.31
• Debt-to-Equity: 1.11
• Cash Position: $740.76M
• Operating Margin: 13.6
• Total Assets: $5.36B
• Total Debt: $1.20B

Key Executives

• Balkrishan "BK" Kalra
• Abigail P. Johnson

Industry Context

Genpact operates in the business process management (BPM) and digital transformation services industry. This sector is characterized by intense competition, with companies vying for market share through innovation, cost-efficiency, and the ability to offer end-to-end solutions. Key trends include the increasing adoption of AI, automation, and cloud technologies to drive efficiency and deliver enhanced customer experiences.

Top Tags

financial-reporting (6) · 10-Q (5) · governance (4) · financials (4) · institutional-ownership (4) · amendment (4) · Financial Performance (3) · executive-compensation (3) · 8-k (3) · corporate-governance (3)

Key Numbers

• Net Revenues: $3.76B — Increased by 6.89% for the nine months ended September 30, 2025, compared to $3.52B in 2024.
• Net Income: $409.4M — Increased by 10.13% for the nine months ended September 30, 2025, compared to $371.8M in 2024.
• Diluted EPS: $2.31 — Increased from $2.06 for the nine months ended September 30, 2024, to $2.31 in 2025.
• Current Portion of Long-Term Debt: $375.87M — Increased significantly from $26.17M as of December 31, 2024, to $375.87M as of September 30, 2025.
• Net Cash Provided by Operating Activities: $526.16M — Increased from $412.18M for the nine months ended September 30, 2024, to $526.16M in 2025.
• Net Cash Used for Investing Activities: $123.64M — Increased from $64.71M for the nine months ended September 30, 2024, to $123.64M in 2025, driven by acquisitions.
• Payment for Business Acquisitions: $80.38M — New expenditure for the nine months ended September 30, 2025, contributing to increased investing activities.
• Payment for Stock Repurchased and Retired: $183.02M — Increased from $167.66M for the nine months ended September 30, 2024, to $183.02M in 2025.
• Accumulated Other Comprehensive Loss: $822.47M — Worsened from $(794.09)M as of December 31, 2024, to $(822.47)M as of September 30, 2025.
• Common Shares Outstanding: 172,409,091 — Decreased from 174,661,943 as of December 31, 2024, due to stock repurchases.
• SEC File Number: 001-33626 — Identifies the company's filing history with the SEC.
• I.R.S. Employer Identification No.: 98-0533350 — Company's tax identification number.
• Revenue (H1 2025): $2.35B — Up 8% from H1 2024, indicating strong top-line growth.
• Net Income (Q2 2025): $185M — Increased 15.6% year-over-year, showcasing enhanced profitability.
• Net Income Growth: 15.6% — Percentage increase in net income from Q2 2024 to Q2 2025, highlighting operational efficiency.

Forward-Looking Statements

• {"claim":"FMR LLC will maintain a significant ownership stake in Genpact LTD.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}

Related Companies

ACN · TCS · INFY

Frequently Asked Questions